High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.

Saved in:
Bibliographic Details
Title: High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.
Authors: Nie Y; Division of Medical Oncology, University of Colorado, Aurora, CO., Staley A; Department of Biostatistics, University of Colorado, Aurora, CO., Hinz TK; Department of Craniofacial Biology, University of Colorado, Aurora, CO., Perez-Johnston R; Department of Radiology, University of Colorado, Aurora, CO., Merrick DT; Department of Pathology, University of Colorado, Aurora, CO., Yang MC; Department of Pathology, University of Colorado, Aurora, CO., Davies KD; Department of Pathology, University of Colorado, Aurora, CO., Bunn PA; Division of Medical Oncology, University of Colorado, Aurora, CO., Aisner DL; Department of Pathology, University of Colorado, Aurora, CO., Camidge DR; Division of Medical Oncology, University of Colorado, Aurora, CO., Schenk EL; Division of Medical Oncology, University of Colorado, Aurora, CO., Heasley LE; Department of Craniofacial Biology, University of Colorado, Aurora, CO; Eastern Colorado VA Healthcare System, Rocky Mountain Regional VA Medical Center, Aurora, CO., Patil T; Division of Medical Oncology, University of Colorado, Aurora, CO. Electronic address: tejas.patil@cuanschutz.edu.
Source: Clinical lung cancer [Clin Lung Cancer] 2026 Jun; Vol. 27 (5), pp. 96-105. Date of Electronic Publication: 2026 Apr 30.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0690
DOI:10.1016/j.cllc.2026.04.010